is an uncommon cause of prosthetic valve endocarditis (PVE). Recommended antimicrobial therapy typically includes intravenous β-lactams with or without synergistic aminoglycosides. studies have previously identified antagonism when rifampicin has been used in combination with β-lactams. However, data of rifampicin use are limited despite its enhanced anti-biofilm activity. A 63-year-old male presented with fever and back pain. bacteraemia and bioprosthetic aortic valve endocarditis was confirmed, along with spinal discitis and osteomyelitis. He was successfully treated with benzylpenicillin and rifampicin, in conjunction with valve replacement. Rifampicin remains an alternate agent to use, when there are contraindications to traditional aminoglycoside therapy. Further data on rifampicin use in PVE are awaited.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361637 | PMC |
http://dx.doi.org/10.1099/jmmcr.0.005085 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!